GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Sernova Biotherapeutics Inc (OTCPK:SEOVF) » Definitions » Gross Margin %

SEOVF (Sernova Biotherapeutics) Gross Margin % : 0.00% (As of Oct. 2024)


View and export this data going back to 1998. Start your Free Trial

What is Sernova Biotherapeutics Gross Margin %?

Gross Margin % is calculated as gross profit divided by its revenue. Sernova Biotherapeutics's Gross Profit for the three months ended in Oct. 2024 was $0.00 Mil. Sernova Biotherapeutics's Revenue for the three months ended in Oct. 2024 was $0.00 Mil. Therefore, Sernova Biotherapeutics's Gross Margin % for the quarter that ended in Oct. 2024 was 0.00%. If there's no value for Cost of Goods Sold, then Gross Margin % is not calculated.


The historical rank and industry rank for Sernova Biotherapeutics's Gross Margin % or its related term are showing as below:


SEOVF's Gross Margin % is not ranked *
in the Biotechnology industry.
Industry Median: 60.3
* Ranked among companies with meaningful Gross Margin % only.

Sernova Biotherapeutics had a gross margin of N/A% for the quarter that ended in Oct. 2024 => No sustainable competitive advantage

The 5-Year average Growth Rate of Gross Margin for Sernova Biotherapeutics was 0.00% per year.


Sernova Biotherapeutics Gross Margin % Historical Data

The historical data trend for Sernova Biotherapeutics's Gross Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Sernova Biotherapeutics Gross Margin % Chart

Sernova Biotherapeutics Annual Data
Trend Oct15 Oct16 Oct17 Oct18 Oct19 Oct20 Oct21 Oct22 Oct23 Oct24
Gross Margin %
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - -

Sernova Biotherapeutics Quarterly Data
Jan20 Apr20 Jul20 Oct20 Jan21 Apr21 Jul21 Oct21 Jan22 Apr22 Jul22 Oct22 Jan23 Apr23 Jul23 Oct23 Jan24 Apr24 Jul24 Oct24
Gross Margin % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of Sernova Biotherapeutics's Gross Margin %

For the Biotechnology subindustry, Sernova Biotherapeutics's Gross Margin %, along with its competitors' market caps and Gross Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Sernova Biotherapeutics's Gross Margin % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Sernova Biotherapeutics's Gross Margin % distribution charts can be found below:

* The bar in red indicates where Sernova Biotherapeutics's Gross Margin % falls into.



Sernova Biotherapeutics Gross Margin % Calculation

Gross Margin is the percentage of Gross Profit out of sales or Revenue. (Note that if there's no value for Cost of Goods Sold, then Gross Margin % is not calculated.)

Sernova Biotherapeutics's Gross Margin for the fiscal year that ended in Oct. 2024 is calculated as

Gross Margin % (A: Oct. 2024 )=Gross Profit (A: Oct. 2024 ) / Revenue (A: Oct. 2024 )
=0 / 0
=(Revenue - Cost of Goods Sold) / Revenue
=(0 - 0) / 0
=N/A %

Sernova Biotherapeutics's Gross Margin for the quarter that ended in Oct. 2024 is calculated as


Gross Margin % (Q: Oct. 2024 )=Gross Profit (Q: Oct. 2024 ) / Revenue (Q: Oct. 2024 )
=0 / 0
=(Revenue - Cost of Goods Sold) / Revenue
=(0 - 0) / 0
=N/A %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

A positive Gross Profit is only the first step for a company to make a net profit. The gross profit needs to be big enough to also cover related labor, equipment, rental, marketing/advertising, research and development and a lot of other costs in selling the products.


Sernova Biotherapeutics  (OTCPK:SEOVF) Gross Margin % Explanation

Warren Buffett believes that firms with excellent long term economics tend to have consistently higher margins.

Durable competitive advantage creates a high Gross Margin % because of the freedom to price in excess of cost. Companies can be categorized by their Gross Margin %

1. Greater than 40% = Durable competitive advantage
2. Less than 40% = Competition eroding margins
3. Less than 20% = no sustainable competitive advantage
Consistency of Gross Margin is key

Sernova Biotherapeutics had a gross margin of N/A% for the quarter that ended in Oct. 2024 => No sustainable competitive advantage


Be Aware

If a company loses its competitive advantages, usually its gross margin declines well before its sales declines. Watching Gross Margin % and Operating Margin % closely helps avoid value trap situations.


Sernova Biotherapeutics Gross Margin % Related Terms

Thank you for viewing the detailed overview of Sernova Biotherapeutics's Gross Margin % provided by GuruFocus.com. Please click on the following links to see related term pages.


Sernova Biotherapeutics Business Description

Traded in Other Exchanges
Address
700 Collip Circle, Suite 114, London, ON, CAN, N6G 4X8
Sernova Biotherapeutics Inc is a clinical-stage company developing regenerative medicines. The company develops Cell Pouch with human donor cells or stem cells to create a biohybrid organ. The Cell Pouch is a implantable medical device designed to create a vascularized organ-like environment for the transplantation and engraftment of therapeutic cells, which then release proteins, hormones, or other factors into the bloodstream for the long-term treatment of multiple chronic diseases such as type 1 diabetes, hypothyroid disease, and rare diseases such as hemophilia A.